Get startedLog in
    Picture of Xeris Biopharma Holdings logo

    XERS — Xeris Biopharma Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    Brief: Xeris Biopharma Announces Plans For A Phase Ii Dose-Finding Study For Its Investigational Subcutaneous (SC) Levothyroxine (Xp-8121) As Replacement Therapy For Hypothyroidism

    Picture of Xeris Biopharma Holdings logoXeris Biopharma Holdings
    15/12/2022 14:07
    Dec 15 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ANNOUNCES PLANS FOR A PHASE II
DOSE-FINDING
STUDY FOR ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE
(XP-8121) AS REPLACEMENT THERAPY FOR HYPOTHYROIDISM
    * XERIS BIOPHARMA HOLDINGS INC - TARGETING INITIATION OF A
PHASE
II STUDY BY 2H 2023

Source text for Eikon:  ID:nBw6sRFMDa 
Further company coverage:  XERS.O 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Xeris Biopharma Holdings

    See all news